# LPL

## Overview
The LPL gene encodes the enzyme lipoprotein lipase, a crucial component in lipid metabolism. Lipoprotein lipase is a glycoprotein enzyme that functions primarily as a hydrolase, catalyzing the breakdown of triglycerides in lipoproteins such as chylomicrons and very low-density lipoproteins (VLDLs) into free fatty acids and glycerol. This enzymatic activity is essential for the uptake and utilization of fatty acids in various tissues, including adipose tissue, skeletal muscle, and the heart (Kersten2014Physiological; Wang2009Lipoprotein). The LPL gene is subject to complex regulatory mechanisms at multiple levels, ensuring precise control over lipoprotein lipid uptake and energy homeostasis (Wang2009Lipoprotein). Mutations in the LPL gene can lead to disorders such as familial chylomicronemia syndrome and hypertriglyceridemia, highlighting its clinical significance in lipid metabolism and cardiovascular health (Zhang2023Frameshift; Gotoda1991Heterogeneous).

## Structure
Lipoprotein lipase (LPL) is a 55-kDa glycoprotein composed of approximately 448 amino acids, forming a polypeptide chain that includes both alpha-helices and beta-sheets in its secondary structure (Kristensen2021GPIHBP1; van1994Lipoprotein). The protein is organized into two main domains: an N-terminal α/β-hydrolase fold containing a catalytic triad and a lid segment, and a C-terminal β-barrel domain important for lipid binding (Kristensen2021GPIHBP1). The C-terminal domain adopts a PLAT fold, which is crucial for its function (Kristensen2021GPIHBP1).

LPL typically forms a homodimer in its quaternary structure, although it can also exist as a monomer, which is stable and active (Kristensen2021GPIHBP1). The dimeric form is stabilized by interactions with heparan sulfate proteoglycans and GPIHBP1, which enhance its thermal stability and active conformation (Kristensen2021GPIHBP1).

Post-translational modifications of LPL include glycosylation, which occurs in the endoplasmic reticulum and is essential for its proper folding and function (Wang2009Lipoprotein). The protein's structure is further stabilized by calcium, which is necessary for its correct folding and activity (Kristensen2021GPIHBP1). The presence of heparin-binding motifs on LPL's surface facilitates its interaction with the extracellular matrix, playing a significant role in its regulation and function (van1994Lipoprotein).

## Function
Lipoprotein lipase (LPL) is an enzyme that plays a critical role in lipid metabolism by hydrolyzing triglycerides in chylomicrons and very low-density lipoproteins (VLDLs) into free fatty acids and glycerol. This process occurs primarily on the endothelial surface of capillaries in tissues such as adipose tissue, skeletal muscle, and the heart, facilitating the uptake of fatty acids for energy storage or utilization (Kersten2014Physiological; Wang2009Lipoprotein). 

LPL functions as a noncovalent active homodimer and requires the presence of the cofactor apoC-II for its activation. The enzyme consists of an amino-terminal domain containing a catalytic triad responsible for lipolysis and a carboxyl-terminal domain important for binding lipoproteins (Wang2009Lipoprotein). Beyond its enzymatic activity, LPL also facilitates the anchoring of lipoproteins to the vessel wall, promoting lipoprotein particle uptake and lipid exchange between lipoproteins. It acts as a ligand for lipoprotein receptors, aiding in lipoprotein uptake and mediating the selective uptake of lipoprotein-associated lipids and lipophilic vitamins (Wang2009Lipoprotein).

LPL is synthesized in parenchymal cells and transported to the luminal surface of vascular endothelial cells, where it is anchored by interactions with heparin sulfate proteoglycans (Wang2009Lipoprotein). Its activity is regulated at multiple levels, including transcriptional, posttranscriptional, translational, and posttranslational, allowing for localized control of lipoprotein lipid uptake, which affects energy homeostasis and insulin action (Wang2009Lipoprotein).

## Clinical Significance
Mutations in the LPL gene can lead to several lipid metabolism disorders, most notably familial chylomicronemia syndrome (FCS) and hypertriglyceridemia (HTG). FCS is an autosomal recessive disorder characterized by extremely high plasma triglyceride levels, leading to symptoms such as abdominal pain, eruptive xanthomas, lipemia retinalis, hepatosplenomegaly, and acute pancreatitis (Zhang2023Frameshift; Gotoda1991Heterogeneous). The condition is primarily caused by homozygous or compound heterozygous variants in the LPL gene, which result in a complete or partial loss of LPL function (Zhang2023Frameshift).

LPL deficiency is associated with a variety of mutations, including frameshift, nonsense, and missense mutations, which can affect the enzyme's catalytic activity and secretion (Zhang2023Frameshift; Gotoda1991Heterogeneous). These mutations often lead to decreased or absent LPL activity, contributing to severe hypertriglyceridemia and its complications (Gotoda1991Heterogeneous; Surendran2012Mutations).

In some cases, LPL gene mutations can also result in milder phenotypes, depending on the residual enzyme activity. For instance, certain frameshift variants may retain some LPL function, delaying the onset of FCS and reducing the severity of associated symptoms (Zhang2023Frameshift). Understanding the genotype-phenotype relationship in LPL variants is crucial for improving the prevention and treatment of HTG-related conditions (Zhang2023Frameshift).

## Interactions
Lipoprotein lipase (LPL) interacts with several proteins that regulate its activity and stability. One key interaction is with glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1), which stabilizes LPL and facilitates its transport to the capillary lumen. GPIHBP1 binds to the carboxy-terminal domain of LPL, forming a complex that prevents LPL from unfolding and maintains its activity (Young2019GPIHBP1).

LPL also interacts with angiopoietin-like protein 4 (ANGPTL4), which inhibits LPL by converting it from an active dimer to an inactive monomer. This interaction occurs near the active site of LPL, particularly at the lid domain, and is crucial for regulating LPL activity in response to nutritional cues (Gutgsell2019Mapping; Sukonina2006Angiopoietinlike).

Additionally, LPL requires the cofactor apolipoprotein C-II for activation. This interaction occurs at specific regions in the amino-terminal domain of LPL, which are essential for its lipolytic function (Wang2009Lipoprotein). These interactions are critical for the regulation of lipid metabolism and have significant implications for conditions such as hypertriglyceridemia and cardiovascular disease.


## References


[1. (Young2019GPIHBP1) Stephen G. Young, Loren G. Fong, Anne P. Beigneux, Christopher M. Allan, Cuiwen He, Haibo Jiang, Katsuyuki Nakajima, Muthuraman Meiyappan, Gabriel Birrane, and Michael Ploug. Gpihbp1 and lipoprotein lipase, partners in plasma triglyceride metabolism. Cell Metabolism, 30(1):51–65, July 2019. URL: http://dx.doi.org/10.1016/j.cmet.2019.05.023, doi:10.1016/j.cmet.2019.05.023. This article has 92 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cmet.2019.05.023)

[2. (Kristensen2021GPIHBP1) Kristian Kølby Kristensen, Katrine Zinck Leth-Espensen, Anni Kumari, Anne Louise Grønnemose, Anne-Marie Lund-Winther, Stephen G. Young, and Michael Ploug. Gpihbp1 and angptl4 utilize protein disorder to orchestrate order in plasma triglyceride metabolism and regulate compartmentalization of lpl activity. Frontiers in Cell and Developmental Biology, July 2021. URL: http://dx.doi.org/10.3389/fcell.2021.702508, doi:10.3389/fcell.2021.702508. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.702508)

[3. (Sukonina2006Angiopoietinlike) Valentina Sukonina, Aivar Lookene, Thomas Olivecrona, and Gunilla Olivecrona. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proceedings of the National Academy of Sciences, 103(46):17450–17455, November 2006. URL: http://dx.doi.org/10.1073/pnas.0604026103, doi:10.1073/pnas.0604026103. This article has 325 citations.](https://doi.org/10.1073/pnas.0604026103)

[4. (Gotoda1991Heterogeneous) T Gotoda, N Yamada, M Kawamura, K Kozaki, N Mori, S Ishibashi, H Shimano, F Takaku, Y Yazaki, and Y Furuichi. Heterogeneous mutations in the human lipoprotein lipase gene in patients with familial lipoprotein lipase deficiency. Journal of Clinical Investigation, 88(6):1856–1864, December 1991. URL: http://dx.doi.org/10.1172/jci115507, doi:10.1172/jci115507. This article has 97 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci115507)

[5. (Gutgsell2019Mapping) Aspen R. Gutgsell, Swapnil V. Ghodge, Albert A. Bowers, and Saskia B. Neher. Mapping the sites of the lipoprotein lipase (lpl)–angiopoietin-like protein 4 (angptl4) interaction provides mechanistic insight into lpl inhibition. Journal of Biological Chemistry, 294(8):2678–5366, February 2019. URL: http://dx.doi.org/10.1074/jbc.ra118.005932, doi:10.1074/jbc.ra118.005932. This article has 37 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.ra118.005932)

[6. (Zhang2023Frameshift) Guofu Zhang, Yuepeng Hu, Qi Yang, Na Pu, Gang Li, Jingzhu Zhang, Zhihui Tong, Emmanuelle Masson, David N. Cooper, Jian-Min Chen, and Weiqin Li. Frameshift coding sequence variants in the lpl gene: identification of two novel events and exploration of the genotype–phenotype relationship for variants reported to date. Lipids in Health and Disease, August 2023. URL: http://dx.doi.org/10.1186/s12944-023-01898-w, doi:10.1186/s12944-023-01898-w. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12944-023-01898-w)

[7. (Kersten2014Physiological) Sander Kersten. Physiological regulation of lipoprotein lipase. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1841(7):919–933, July 2014. URL: http://dx.doi.org/10.1016/j.bbalip.2014.03.013, doi:10.1016/j.bbalip.2014.03.013. This article has 375 citations.](https://doi.org/10.1016/j.bbalip.2014.03.013)

[8. (Wang2009Lipoprotein) Hong Wang and Robert H. Eckel. Lipoprotein lipase: from gene to obesity. American Journal of Physiology-Endocrinology and Metabolism, 297(2):E271–E288, August 2009. URL: http://dx.doi.org/10.1152/ajpendo.90920.2008, doi:10.1152/ajpendo.90920.2008. This article has 619 citations.](https://doi.org/10.1152/ajpendo.90920.2008)

[9. (Surendran2012Mutations) R. P. Surendran, M. E. Visser, S. Heemelaar, J. Wang, J. Peter, J. C. Defesche, J. A. Kuivenhoven, M. Hosseini, M. Péterfy, J. J. P. Kastelein, C. T. Johansen, R. A. Hegele, E. S. G. Stroes, and G. M. Dallinga‐Thie. Mutations in lpl, apoc2, apoa5, gpihbp1 and lmf1 in patients with severe hypertriglyceridaemia. Journal of Internal Medicine, 272(2):185–196, February 2012. URL: http://dx.doi.org/10.1111/j.1365-2796.2012.02516.x, doi:10.1111/j.1365-2796.2012.02516.x. This article has 201 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/j.1365-2796.2012.02516.x)

[10. (van1994Lipoprotein) H. van Tilbeurgh, A. Roussel, J.M. Lalouel, and C. Cambillau. Lipoprotein lipase. molecular model based on the pancreatic lipase x-ray structure: consequences for heparin binding and catalysis. Journal of Biological Chemistry, 269(6):4626–4633, February 1994. URL: http://dx.doi.org/10.1016/s0021-9258(17)41822-9, doi:10.1016/s0021-9258(17)41822-9. This article has 150 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(17)41822-9)